ACTR-IC Activators
ACTR-IC activators form a specialized category of compounds that are capable of modulating the activity of the protein known as ACTR-IC. However, without specific details on the protein ACTR-IC, I will provide a general overview of how protein activators operate, assuming that ACTR-IC is a protein that can be targeted by such molecules.
Activators of proteins like ACTR-IC often function by binding to the protein itself or by interacting with its regulatory components to enhance its activity. This activation may alter the protein's conformation, increase its affinity for substrates or other interacting molecules, or stabilize forms of the protein that are more functionally active. The direct binding of activators may mimic the effects of natural ligands or cofactors, facilitating the protein's inherent activity. If the protein ACTR-IC is involved in a particular signaling pathway, activators may also exert their effects indirectly by upregulating the signaling cascade that leads to the activation of ACTR-IC. This could involve the modulation of upstream kinases, phosphatases, or other regulatory proteins that control the phosphorylation states, localization, or degradation of ACTR-IC. In doing so, activators can enhance the protein's role within its respective pathway.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC). PKC phosphorylates SMAD proteins, which are downstream effectors in the ACTR-IC signaling pathway. This phosphorylation enhances the SMAD proteins' ability to transduce signals from ACTR-IC, thereby amplifying ACTR-IC's functional activity. | ||||||
1,2-Dioctanoyl-sn-glycerol | 60514-48-9 | sc-202397 sc-202397A | 10 mg 50 mg | $47.00 $254.00 | 2 | |
DAG is a second messenger that activates PKC. Activated PKC phosphorylates SMAD proteins, enhancing their ability to transduce signals from ACTR-IC and therefore increasing ACTR-IC's functional activity. | ||||||
1-Oleoyl-2-acetyl-sn-glycerol (OAG) | 86390-77-4 | sc-200417 sc-200417A | 10 mg 50 mg | $119.00 $453.00 | 1 | |
OAG is an analog of DAG and activates PKC. The activated PKC phosphorylates SMAD proteins, thereby amplifying the signal transduction from ACTR-IC and enhancing its functional activity. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, leading to an increase in cAMP. The increased cAMP can activate PKA, which phosphorylates SMAD proteins and enhances their signaling in response to ACTR-IC activation. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine can activate PKC at nanomolar concentrations. The activated PKC phosphorylates SMAD proteins, leading to an enhancement of signal transduction from ACTR-IC. | ||||||
Bryostatin 1 | 83314-01-6 | sc-201407 | 10 µg | $245.00 | 9 | |
Bryostatin 1 is a potent activator of PKC. PKC phosphorylation of SMAD proteins enhances their ability to mediate signals from ACTR-IC, thereby increasing ACTR-IC's functional activity. | ||||||
Zoledronic acid, anhydrous | 118072-93-8 | sc-364663 sc-364663A | 25 mg 100 mg | $92.00 $256.00 | 5 | |
Zoledronic acid inhibits farnesyl diphosphate synthase, leading to reduced prenylation of small GTPases. This can enhance ACTR-IC activity by reducing competition for SMAD interaction and signaling. | ||||||
Manumycin A | 52665-74-4 | sc-200857 sc-200857A | 1 mg 5 mg | $219.00 $634.00 | 5 | |
Manumycin A inhibits farnesyltransferase, which reduces prenylation of small GTPases. This enhances ACTR-IC activity by minimizing competition for SMAD interaction and enhancing downstream signaling. | ||||||
GGTI 298 | 1217457-86-7 | sc-361184 sc-361184A | 1 mg 5 mg | $193.00 $838.00 | 2 | |
GGTI-298 inhibits geranylgeranyltransferase, preventing prenylation of small GTPases. This can enhance ACTR-IC activity by reducing competition for SMAD interaction and signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, reducing Akt signaling. This can enhance ACTR-IC activity by reducing the inhibitory phosphorylations on SMAD proteins. | ||||||